^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CEACAM5 expression

    i
    Other names: CEACAM5, CEA Cell Adhesion Molecule 5, Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5, Meconium Antigen 100, CD66e, Carcinoembryonic Antigen, CD66e Antigen
    Entrez ID:
    1048
    Related biomarkers:
    Expression
    11ms
    BP42675: Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment (clinicaltrials.gov)
    P1/2, N=54, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | N=80 --> 54
    Trial completion • Enrollment change
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 overexpression
    |
    Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)
    11ms
    Prediction of Synchronous Serum CEA Expression Status Based on Baseline MRI Features of Primary Rectal Cancer Lesions Pre-treatment: A Retrospective Study. (PubMed, Sci Rep)
    Decision curve analysis indicated the clinical value of the nomogram. We developed a visual nomogram to predict high baseline CEA expression for patients with rectal cancer, enabling clinicians to conduct a personalized risk assessment and therapy.
    Retrospective data • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    12ms
    Sex-based differences in CEACAM5 expression in lung cancer. (PubMed, Transl Cancer Res)
    High CEACAM5 expression in lung adenocarcinoma is associated with worse survival among female patients. The biologic impact of sex on CEACAM5 as a biomarker warrants further study.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 overexpression
    12ms
    Carcinoembryonic Antigen Expression in Human Tumors: A Tissue Microarray Study on 13,725 Tumors. (PubMed, Cancers (Basel))
    The comprehensive list of CEA-positive human tumor types demonstrates that CEA is expressed in a broad range of epithelial neoplasms, many of which might benefit from CEA serum monitoring and anti-CEA therapies.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 overexpression • CEACAM5 positive
    12ms
    CARMEN-LC06: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (clinicaltrials.gov)
    P2, N=22, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, the decision is not related to any safety concern.
    Trial termination
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    1year
    CEACAM5: Evaluation of SAR408701 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=254, Terminated, Sanofi | Active, not recruiting --> Terminated; Sponsor decision, The decision is not related to any safety concern.
    Trial termination • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression • CEACAM5 positive
    |
    tusamitamab ravtansine (SAR408701)
    1year
    Efficacy and safety of osimertinib plus bevacizumab versus osimertinib alone for advanced non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials. (PubMed, Medicine (Baltimore))
    For patients with advanced EGFR-mutant NSCLC, osimertinib plus bevacizumab has some clinical benefit compared with osimertinib alone. Still, it does not provide additional long-term survival benefits and has higher toxicity. More well-designed, multicenter RCTs are needed to identify the subgroups of patients most likely to benefit from this combination regimen and to validate the optimal dose of this combination regimen.
    Clinical • Retrospective data • Journal • Metastases
    |
    EGFR (Epidermal growth factor receptor) • CEACAM5 (CEA Cell Adhesion Molecule 5) • KRT19 (Keratin 19)
    |
    EGFR mutation • CEACAM5 expression
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib)
    1year
    Structural insights into epitope-paratope interactions of a monoclonal antibody targeting CEACAM5-expressing tumors. (PubMed, Nat Commun)
    The antibody-drug conjugate tusamitamab ravtansine specifically recognizes the A3-B3 domains of human CEACAM5 (hCEACAM5)...The cryogenic electron microscopy structure of the hCEACAM5A3-B3- tusa Fab complex (3.11 Å overall resolution) reveals a discontinuous epitope involving residues in the A3-B3 domains and an N-linked mannose at residue Asn612. Conformational constraints on the epitope-paratope interface enable tusamitamab to target hCEACAM5A3-B3 and distinguish CEACAM5 from other CEACAMs.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    1year
    A study of the clinical significance of mSEPT9 in monitoring recurrence and prognosis in patients with surgically treated colorectal cancer. (PubMed, PLoS One)
    The detection of mSEPT9 combined with CEA in preoperative plasma helps predict recurrence in colorectal cancer patients.
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • SEPTIN9 (Septin 9)
    |
    CEACAM5 expression
    1year
    Novel anti-CEA affibody for rapid tumor-targeting and molecular imaging diagnosis in mice bearing gastrointestinal cancer cell lines. (PubMed, Front Microbiol)
    The Dylight755-labeled ZCEA affibody exhibited high tumor-targeting specificity in CEA+ xenograft-bearing mice and possesses promising characteristics for tumor-targeting imaging. Overall, our results suggest the potential use of ZCEA affibodies as fluorescent molecular imaging probes for detecting CEA expression in gastrointestinal cancer.
    Preclinical • Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    1year
    CARMEN-LC06: Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Sanofi | Trial completion date: Sep 2024 --> Dec 2024
    Trial completion date
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    CEACAM5 expression
    |
    tusamitamab ravtansine (SAR408701)
    1year
    EVEREST-1: initial safety data from a seamless phase 1/2 study of A2B530, a logic-gated Tmod CAR T-cell therapy, in patients with solid tumors associated with CEA expression also exhibiting HLA-LOH (SITC 2024)
    β2M shRNA, beta–2–microglobulin short–hairpin RNA; CD, cluster of differentiation; EF1α, elongation factor–1 alpha; LIR, leukocyte immunoglobulin–like receptor; scFv, single–chain variable fragment; T2A, thosea asigna virus 2ADownload figure Open in new tab Download powerpoint Abstract 588 Figure 2 EVEREST-1 study design. BOIN, Bayesian optimal interval design; PCLD, preconditioning lymphodepletion; RP2D, recommended phase 2 dose
    Clinical • P1/2 data • CAR T-Cell Therapy
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • B2M (Beta-2-microglobulin) • GZMB (Granzyme B)
    |
    CEACAM5 expression • HLA-A*02
    |
    Tempus HLA-LOH assay
    |
    A2B530